ArticleCirculation. Heart failure2022
Development of Advanced Heart Failure: A Population-Based Study.
Article in Circulation. Heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- The Dynamic Nature of Caregiving in Advanced Heart Failure With Left Ventricular Assist Device Support: A Systematic Review and Thematic Synthesis.Current heart failure reports · 2026Pooled it
- Cost-Effectiveness of NT-proBNP-Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real-World Evidence From the Hong Kong Diabetes Biobank.Diabetes, obesity & metabolism · 2026Article
- Closing the gap between trial and clinical reality in long-term left ventricular assist device use outcomes.ESC heart failure · 2026Article
- SIENA Score and CVP/PCWP Predict Mid-Term Prognosis After LVAD Implantation: A Single-Center Study.Journal of cardiovascular development and disease · 2026Article
- Palliative Care in Advanced Heart Failure.Current heart failure reports · 2026Review
- A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.Cardiac failure review · 2026Review
- Costs of medical treatment of advanced heart failure: a scoping review.Systematic reviews · 2025Article
- The Cost of Medical Management in Advanced Heart Failure: A Latin American Perspective.Arquivos brasileiros de cardiologia · 2025Article
- Artificial Intelligence-Guided Neuromodulation in Heart Failure with Preserved and Reduced Ejection Fraction: Mechanisms, Evidence, and Future Directions.Journal of cardiovascular development and disease · 2025Review
- Knowledge and application of ESC/HFA guidelines in the management of advanced heart failure.European journal of heart failure · 2025Article
- Burden of Treatment in Patients With Heart Failure.Journal of the American Heart Association · 2025Article
- The Hidden Cost of Denied Access: Advanced Heart Failure in Latin America.Arquivos brasileiros de cardiologia · 2025Article
- Current Review of Heart Failure-Related Risk and Prognostic Factors.Biomedicines · 2024Review
- Contemporary clinical role of echocardiography in patients with advanced heart failure.Heart failure reviews · 2024Review
- Advanced Heart Failure Characteristics and Outcomes in Women and Men.Journal of the American Heart Association · 2024Article
- Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape.Heart failure reviews · 2024Review
- The sympathetic nervous system in heart failure revisited.Heart failure reviews · 2024Review
- Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP-HF registry.ESC heart failure · 2024Article
- Multimodality Imaging in Advanced Heart Failure for Diagnosis, Management and Follow-Up: A Comprehensive Review.Journal of clinical medicine · 2023Review
- Advanced Heart Failure Characteristics and Outcomes in Commercially Insured U.S. Adults.JACC. Heart failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSome patients with heart failure (HF) will go on to develop advanced HF, characterized by severe HF symptoms despite attempts to optimize medical therapy. The goals of this study were to examine the risk of developing advanced HF in patients with newly diagnosed HF, identify risk factors for developing advanced HF, and evaluate the impact of advanced HF on outcomes.
methodsThis was a population-based, retrospective cohort study of Olmsted County, Minnesota, residents with a new clinical diagnosis of HF between 2007 and 2017. Risk factors for the development of advanced HF (2018 European Society of Cardiology criteria) were examined using cause-specific Cox proportional hazard regression models. The associations of development of advanced HF with risks of hospitalization and mortality were examined using the Andersen-Gill and Cox models, respectively.
resultsThere were 4597 residents with incident HF from 2007 to 2017. The cumulative incidence of advanced HF was 11.5% (95% CI, 10.5%-12.5%) at 6 years after incident HF diagnosis overall and was 14.4% (95% CI, 12.3%-16.9%), 11.4% (95% CI, 8.9%-14.6%), and 11.7% (95% CI, 10.3%-13.2%) in patients with incident HF with reduced, mildly reduced, and preserved ejection fraction, respectively. Key demographics, comorbidities, and echocardiographic characteristics were independently associated with the development of advanced HF. Development of advanced HF was associated with increased risks of all-cause hospitalization (adjusted hazard ratio, 3.0 [95% CI, 2.7-3.4];
conclusionsIn this population-based study, development of advanced HF was common and was associated with markedly increased morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.